Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18976503 | 0.98 | GNAI3 (0.34) | GNAI3GNAO1GNAI1OPRM1 | |
| SCHEMBL19251213 | 0.84 | GNAI3 (0.40) | GNAI3GNAO1GNAI1SPHK1OPRM1 | |
| SCHEMBL23776741 | 0.81 | DPP4 (0.31) | — | |
| SCHEMBL24788378 | 0.81 | SPHK1 (0.34) | GNAI3GNAO1GNAI1SPHK1FDPS | |
| SCHEMBL23219692 | 0.80 | GNAI3 (0.31) | GNAI3GNAO1GNAI1 | |
| SCHEMBL20939986 | 0.80 | GNAI3 (0.31) | GNAI3GNAO1GNAI1 | |
| SCHEMBL22962004 | 0.78 | GNAI3 (0.47) | GNAI3GNAO1GNAI1SPHK1OPRM1 | |
| SCHEMBL22778647 | 0.78 | GNAI3 (0.47) | GNAI3GNAO1GNAI1SPHK1OPRM1 | |
| SCHEMBL22962072 | 0.78 | GNAI3 (0.47) | GNAI3GNAO1GNAI1SPHK1OPRM1 | |
| SCHEMBL22962251 | 0.78 | GNAI3 (0.47) | GNAI3GNAO1GNAI1SPHK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADI4, PADI1, PADI2 | GNAI3 1508/4885GNAO1 3377/4885GNAI1 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.